This article is a review of studies in which endotoxin has been administered to human subjects for experimental purposes. Data are presented in tabular form so the reader can better appreciate the objectives of individual studies. Although the original intention was to focus on the adverse events associated with these studies, unexpected serious adverse events rarely have been reported. ; ANG II, angiotensin II; VP, vasopressin; CD45RA(+) CD45RO(-), naive CD4 and CD8 cells; CD45RA(-) CD45RO(+), memory CD4 and CD8 cells; NPY-L, NPY-like immunoreactivity; rBPI 23 , recombinant bactericidal/permeability-increasing protein; PVR, peripheral vascular resistance; CI, cardiac index; SVRI, systemic vascular resistance index; α-MSH, neuropeptide α-melanocyte stimulating hormone; SOCS-1, SCOS-3, suppressors of cytokine signaling.
INTRODUCTION
To many in the biomedical community, the very notion of endotoxin administration to human subjects conjures up images of the worst days of medical 'research' when live virulent pathogens were administered to unwilling subjects. To the contrary, Gram-negative bacterial endotoxin has been given in various forms to human subjects for well over 100 years for the treatment of malignancies and infection. Originally, endotoxin was given therapeutically for the induction of fever in the hope of curing various infections (e.g. neurosyphilis, gonorrhea), certain forms of arthritis and inflammatory processes of the eye 1, 2 as well as for the treatment of cancer. With the observation of the peculiar phenomenon of decreasing fever with multiple endotoxin administrations, by the late 1940s investigators turned their attention to administering endotoxin under controlled experimental conditions in order to understand endotoxin tolerance better. While some of these studies were conducted in human subjects, extensive investigations were carried out in animals. Given the variable sensitivities to endotoxin among animal species, initially there was an attempt to compare the responses to endotoxin in man with those of experimental animals, as well as to examine the physiological consequences of endotoxin in man.
Today, controlled endotoxin infusion has been widely used as a model system to study new therapeutic agents for inflammation before wider clinical studies are undertaken, and to delineate better the multifaceted human innate and adaptive immune responses to endotoxin. Thus, what began as a therapeutic intervention has evolved into the realm of clinical research under carefully controlled conditions.
The subject of endotoxin infusion to human subjects has been previously examined in two excellent reviews. 3, 4 Consequently, the present review will not repeat in detail the descriptions of the human response to endotoxin described in those publications. Rather, we will place these studies in some historical context and focus on more recent studies of endotoxin infusion. The data from these and selected older studies will be presented in tabular form so the reader can better appreciate the objectives of individual studies. Finally, we originally intended to focus on the adverse events associated with these studies; however, as noted below, unexpected serious adverse events rarely have been reported.
Fever therapy
In the late 19th century, physicians were aware of 'injection fevers' whereby diverse compounds administered to patients, each probably contaminated with bacterial products, induced a fever response. Wagner-Jauregg, an Austrian physician, began artificially inducing fevers in his patients in the 1880s. 5 At this time, syphilis was a wide-spread and unpredictable disease, with neurosyphilis accounting for 20% of all hospitalized mental patients. Despite the use of many agents (e.g. mercuric chloride, organic arsenic), there was little discernible improvement. Based, in part, on studies in 1894 that showed immersion of rabbits in hot baths reduced the severity of erysipelas, 6 clinicians, like Wagner-Jauregg, contemplated the induction of fever in humans for the treatment of infections. Laboratory studies also had shown that heating spirochetes to 40-41°C for 1 h reduced their infectivity.
As with Coley (see below), fever initially was induced with erysipelas, but this approach was abandoned because of the serious, and occasionally lethal, infections that occurred. This effort was followed by use of tuberculin; by 1917, Wagner-Jauregg inoculated 9 paretic patients with blood taken from a patient with vivax malaria, and reported that 6/9 showed 'extensive remission'. The following year, however, he accidentally inoculated four patients with falciparum malaria, three of whom died. Many additional trials of malariotherapy were conducted by other investigators, but none with control groups. Consequently, other techniques of fever therapy were examined: hot baths, radiothermy, and protein shock were used to treat multiple sclerosis, and many central nervous system infections. Temperatures as high as 105-106°F were induced for up to 4 h, and multiple treatments of fever therapy were often required. In 1927, Wagner-Jauregg was awarded the Nobel Prize. His studies led to the wide-spread acceptance of artificially-induced fever in the treatment of several diseases, including gonococcal infections and to modest success in the treatment of chancroid (H. ducryei). 7 While both the induction of erysipelas and malaria had been used with some frequency to induce therapeutic fever, each procedure was complicated by lethal infections. Consequently, some physicians used a whole, killed typhoid vaccine which was fever-inducing, probably due to the endotoxin present in the vaccine. Therefore, in the 1940s, Morgan purified the lipopolysaccharide (LPS) from organisms now known as Salmonella typhi and Salmonella paratyphi, as well as from Shigella. 8 In 1942, Favorite and Morgan administered a low dose of their endotoxin to 11 patients with asymptomatic neurosyphilis and one normal subject for the purpose of inducing therapeutic febrile reactions. 9 A total of 100 ng was given in 1 ml, and this dose was well-tolerated. This was the first known instance of a purified LPS being administered to human subjects. Interestingly, Favorite and Morgan described tolerance to the LPS after repeated injections. The endotoxin resistance was independent of the presence of homologous circu-lating antibody, since the antibody titer was not directly related to the resistant state. Thereafter, during the 1940s, Morgan conducted a series of additional experiments with purified LPS in which he explored the nature of endotoxin tolerance in human subjects. 10 Later, Neva and Morgan injected purified endotoxin of S. typhosa and S. dysenteriae to patients convalescing from typhoid and paratyphoid A fevers and compared their febrile responses to those of healthy subjects. 11 With the advent of antibiotics and potent anti-inflammatory agents, fever therapy had become mainly of historical interest (although it has now been re-introduced to treat certain forms of cancer). However, the interesting properties of tolerance induction following repeated injections of LPS led Morgan, Beeson and others to study the properties of endotoxin in the laboratory. [12] [13] [14] [15] With the demonstration by Shwartzman in the 1920s of conditions leading to hyper-responsiveness to LPS, 16 30 years later Thomas and colleagues conducted landmark studies in animals to examine this phenomenon. 17, 18 These, and other studies, formed the basis for suggestions that overwhelming sepsis, such as seen with meningococcal disease, may share mechanisms operative in the Shwartzman reaction. 19 Following the extensive studies on both the toleranceinducing and stimulatory properties of endotoxin administration in animal models in the 1950s, Greisman and Wolff in the 1960s each embarked on a series of studies in which they infused endotoxin preparations into human subjects to examine responses to endotoxin in man systematically. Over a 30-year period, Wolff and colleagues described hematological and febrile responses in human subjects following endotoxin infusion, measured plasma cortisol, growth hormone and kinin production, and examined circulating tumor necrosis factor (TNF)-α, GM-CSF and interleukin (IL)-1 receptor antagonist expression as well as C5a binding to neutrophils, among their other studies. [20] [21] [22] [23] [24] [25] Greisman and colleagues carefully studied the mechanisms of endotoxin tolerance in animals and in human subjects. They studied its acquisition, 26 including the putative role of reticulo-endothelial phagocytic activity, 27 the role of induced antibodies, and its maintenance during human infection (with typhoid and tularemia). 28 Unlike previous investigators, Greisman administered multiple daily doses of endotoxin, sometimes for as long as 30 days. 29 Interestingly, he noted that the febrile response to injected endotoxin was increased in subjects rendered tolerant, and that endotoxin tolerance did not suppress either the fever or toxemia of typhoid fever.
Coley's toxin 30
In 1890, a surgeon in New York, William Coley, noted that following multiple surgical procedures for an aggressive sarcoma, a patient developed erysipelas at the surgical wound site. Remarkably, this led to a spontaneous and complete regression of the malignancy. Since other physicians had similar observations, Coley intentionally infected patients diagnosed with inoperable cancer with erysipelas. Initially, Coley used live bacteria, but after some patients died of the infection, he switched to a killed bacterial preparation. Since these preparations gave mixed results, he added cultures of Bacillus prodigiosus, a Gram-negative bacterium (now called Serratia marcescens). By 1896, Coley had treated 160 patients.
With the discovery of X-rays in 1896, interest in the Coley toxin for the treatment of cancers diminished, although its use continued. The first systematic study of Coley's vaccine was published in 1907 by Tracy and Beebe. 31 These investigators tested the components of the vaccine alone and in combination, and found that the Gram-negative bacterial fraction had potent antitumor activity of its own, even when injected at a site distant from the tumor. It was not until 1942, when Landsteiner and Chase suggested that blood mononuclear cells had a prominent role in immunity, that an explanation for this observation could be considered. There were at least 15 different preparations of the Coley vaccine, each made without standardization. There also were different dosage regimens, routes of administration and duration of treatment. Hence, it was no surprise that there were mixed results. Parke, Davis made a commercial version of the Coley toxin in 1899 (which it continued to make until 1950), while the Lister Institute in London made a similar preparation. Of note, since 1914 a German company made a preparation, 'Vaccineurin', to induce fevers and sold it over the counter. Despite recommendations at a symposium on the Coley vaccine in 1934 (2 years before his death) that there be a controlled clinical trial, no such study was conducted. Interestingly, the American Cancer Society's Committee on Unproven Methods of Cancer Management added Coley's toxin to its list in 1965, but removed it 10 years later.
In the 1930s and 1940s, Murray Shear at the National Cancer Institute confirmed the antitumor effect of Serratia in mice and reported that endotoxin present in the bacterial cell wall induced a generalized or non-specific immune response. 32 By 1975, Carswell and colleagues identified a molecule, tumor necrosis factor (TNF), induced by LPS, which had tumoricidal activity. 33 It is not clear, however, whether the mechanism of tumoricidal activity of endotoxin might be due to its induction of TNF-α or of the Shwartzman reaction (although it is possible that TNF-α may play a pivotal role in the Shwartzman reaction).
Lipopolysaccharide preparations
The difficulty in evaluating the efficacy of Coley's toxin originated, in part, because of the lack of a standardized preparation. Prior to Morgan's studies, endotoxin was given as typhoid or paratyphoid vaccines composed of heat-killed bacteria. Morgan prepared his own LPS from Shigella and Ebertheria typhosa (now Salmonella). In the 1950s, Westphal and colleagues developed a procedure of preparing purified lipopolysaccharide (hot phenol/water) that is still considered the standard method, and demonstrated that a fraction of the endotoxin molecule obtained after acid hydrolysis, lipid A, was the toxic component of the endotoxin molecule. 34 Different LPS preparations have been used in the increasing number of endotoxin infusion studies that followed. Wolff and colleagues used Lipexal ® (in Europe, Pyrexal ® ), prepared from Salmonella abortus equi by the Westphal laboratory, as well as a preparation S. typhosa endotoxin prepared by Maurice Landy at the National Institute of Health. 2 Many German studies used the Westphal preparation from S. abortus equi which also became their national reference standard. Studies by Greisman and colleagues used the Landy S. typhosa endotoxin as well as a Pseudomonas endotoxin supplied by Baxter Laboratories. In 1976, Rudbach prepared a large batch of LPS from Escherichia coli O113 which he deposited with the Division of Biologics of the US FDA and has been used by the FDA as a reference material. 35 Most of the American studies since that time have used this preparation, designated EC-5. By 1999, the supply of vials of Lot EC-5 became depleted. A new lot of reference endotoxin, designated Clinical Center Reference Endotoxin (CCRE), derived from the original bulk material extracted from E. coli O113, was prepared and tested alongside EC-5 in 20 subjects. 36 Using total leukocyte count, cortisol, Creactive protein and cytokines as end-points, these investigators found that the EC-5 within the vials (but not within the bulk material) had lost potency since it was first prepared.
In addition to the reference endotoxins used for human studies, the use of the Limulus amebocyte assay (LAL) to test for endotoxin contamination in medical devices and pharmaceuticals has led to the need for standard endotoxins for use in those assays. Following an international collaborative study, an Expert Committee on Biological Standardization of the World Health Organization established in 1986 that an ampouled preparation, designated 84/650, be used as the international standard. It was calibrated to the EC-5 in both rabbit pyrogen tests and LAL tests performed by different methodologies. 37 To our knowledge, this preparation has not been used in human endotoxin infusion studies.
One might argue that the modern era of endotoxin investigation was born in the 1960s-1970s. By then, there was an extensive experience with endotoxin biology in animal models, particularly in the study of endotoxin tolerance and hyperactivity, and systematic studies of human endotoxin infusion in man were initiated under carefully controlled conditions. There was also an awareness of that some attention to LPS preparations and standardization would be required in the conduct of these studies.
MATERIALS AND METHODS
This article is a review of studies in which endotoxin was administered to human subjects for experimental purposes. Pub-Med was used for the literature search. 'Human endotoxemia' limited to 'English language' and 'human' and 'publication date until August, 2007' resulted in 1529 articles. 'Endotoxin injection to human' limited to 'English language' and 'human' and 'publication date until August, 2007' resulted in 824 articles. The 824 abstracts were reviewed and 189 articles were chosen for in-depth review. Since many of the articles published before the year 2000 have been extensively reviewed, [2] [3] [4] we focused on the more recent publications, although we did include older studies that were particularly relevant to a particular topic under discussion. Those older studies were usually cited in the text. Data in the tables were compiled from 81 articles and an additional 55 articles were used in the Results section of the text. The other articles were either animal studies, human studies with patients who had infections with endotoxemia or in vitro studies. These articles were excluded from this review. The data on the effect of endotoxin in human subjects and the use of the human endotoxemia model for the evaluation of different therapies were summarized in seven tables. For each table, the objectives of each study, the number of subjects included and the salient conclusions are enumerated. Since the vast majority of studies employed endotoxin doses of 2-4 ng/kg, we did not enumerate the endotoxin dose for each study. Many of the well-established human responses to endotoxin are described in the text without further specific references. Documentation can be found in reviews by Wolff, Burrell and Lowry. [2] [3] [4] Given the ever-expanding number of studies in which humans are administered endotoxin, it is impossible to be all-inclusive. Further, while we tried to include as many studies in tabular form, space limitations required that many studies be described only in the text.
RESULTS

Safety
All articles were reviewed for any potential adverse effect, morbidity or mortality; however, no long-term morbidity or mortality was reported in these more than 1000 healthy volunteers. At a 5 ng/kg dose of EC-5, subjects experienced nausea, vomiting and fever. Consequently, doses of ≤ 4 ng/kg have been subsequently employed. Subjects had exhibited the typical constitutional symptoms enumerated below. The most serious adverse event occurred in one subject who had an episode of asystole lasting > 22 s following the infusion of 2 ng/kg endotoxin 73 min after the infusion. The subject had a basal heart rate of 46-55 beats per minute, suggestive of a high resting vagal tone. This subject was later confirmed to have this underlying condition in a tilt table study whereby the subject exhibited syncope and remained unconscious for 15 s without blood pressure or pulse until laid flat. 38 Since then, four additional subjects developed severe bradycardia or protracted asystole following administration of endotoxin, and each of these subjects later demonstrated increased vagal sensitivity. 39 These experiences emphasize the necessity for monitoring all healthy subjects during the administration of endotoxin. Intravenously administered purified endotoxin can cause shock in humans. After being diagnosed with a malignancy, a laboratory worker self-administered 1 mg of purified S. minnesota endotoxin (equivalent to 3750 times the 4 ng/kg dose used in many infusion studies). After prompt initiation of therapy, she recovered despite having a high cardiac output form of hypotension, abnormal renal and hepatic function, noncardiogenic pulmonary edema and coagulopathy. 39a
Systemic effects of endotoxin infusion (Table 1)
Of all the animals studied, man is the most sensitive to the effects of endotoxin. For example, to achieve in rabbits the same febrile response as in man requires the administration of 10 times the dose of endotoxin. 2 In a recent comparative study, mice required 250 times more LPS than man to achieve similar plasma IL-6 levels. While mice did not exhibit similar physiological responses to the LPS (e.g. unlike humans they become hypothermic), the pattern of cytokine responses were similar. 40 Consequently, the extreme sensitivity of man to infused endotoxin limits the dose that can be given. In turn, these small doses of endotoxin could explain the inability to reproduce in man many of the biological effects of endotoxin observed in animals.
The responses of human subjects to endotoxin infusion are remarkably similar. Typically, within 50-90 min following endotoxin infusion, subjects describe flu-like symptoms such as fatigue, malaise, arthralgias, myalgias, headache, nausea, and often chills that resolve within 3-4 h. [2] [3] [4] Fever, however, is the hallmark of endotoxin infusion. After a latent period up to 120 min, there is a monophasic increase in fever which peaks at 1-2°C above baseline. The fever may last up to 3-4 h (depending on dose) and resolves without residual effect. Pyrogenic tolerance of endotoxin appears within 24 h. Since tolerance occurs in agammaglobulinemic patients, it is not due to the development of antibodies.
The gender and age of the subject may affect the response to endotoxin. In a study of 48 men and 24 The rapid vasodilatation by endotoxin administered concomitantly with rBPI is not mediated by complement or contact system activation. The early vasodilatation is compensated by an increase in cardiac output which, therefore, does not result in arterial hypotension To assess changes in plasma α-MSH during the acute inflammatory response to endotoxin
Results
Challenge with endotoxin causes α-MSH release in normal human subjects with high fever. The positive relationship between increases in circulating α-MSH and high thermal response, together with previous evidence from animal studies, suggest that this neuropeptide is an endogenous modulator of host responses women, Coyle et al. 41 compared the influence of gender on the response to infused endotoxin. They found that men exhibited a greater increase in core temperature and greater maximum increase in mean arterial pressure compared with women; however, there were no detectable differences between the groups in circulating leukocyte count, and cortisol or cytokine levels. Therefore, they concluded that activation of the innate immune system by LPS cannot explain the gender-specific differences. 41 In contrast, in a study of 15 men and 15 women, van Eijk and colleagues 42 observed a stronger pro-inflammatory inflammatory response in women (increased TNF-α, C-reactive protein, LPS binding protein, leucopenia) associated with less attenuation of norepinephrine sensitivity. Inflammatory responses also may differ by age. Older individuals have different acute-phase responses, including an initial hyperreactivity, prolonged inflammatory activity, and a prolonged fever response compared with young individuals. 43 While the effects of human endotoxin infusion on the cardiovascular system and, to a lesser extent, on neuroncognitive as well as pulmonary function have been carefully studied, there have been limited studies of the effects of endotoxin infusion on renal and gastrointestinal function.
Cardiovascular effects
During human endotoxin infusion, there is a depression of left ventricular function that is independent of changes in left ventricular volume or vascular resistance, and similar to changes observed in septic shock. 44 However, even in the presence of significant amounts of TNF-α, IL-6 and IL-8 in the systemic circulation, there does not appear to be easily discernible heart damage based on the levels of cardiac troponin 1 (cTn1), a measure of myocardial muscle damage. 45 At doses of administered endotoxin up to 5 ng/kg, decreases in systemic (mean arterial) blood pressure and orthostatic hypotension have been observed, with an increase in cardiac index and heart rate and a decrease in systemic vascular resistance with the latter lasting up to 5 h as a result of marked vascular adrenoceptor hyporeactivity. 44, 46 Increases in cardiac output may ameliorate the degree of systemic hypotension; however, since the vasodilatation and decrease in peripheral resistance occur in the absence of nitric oxide (NO) activity or iNOS expression, vascular iNOS may not be involved in the systemic vasodilation that occurs during endotoxemia. 46 These hyperdynamic cardiovascular responses can occur in the absence of fever and are not ameliorated by oral cyclooxygenase or phosphodiesterase inhibition. 47 Treatment with rBPI 23 , a recombinant protein with endotoxin-neutralizing activity, had no effect on these hemodynamic responses. 48, 49 The effect of endotoxemia on endothelial cell functions are more thoroughly reviewed below (Table 4) .
Pulmonary effects
Early inflammatory responses to LPS alter lung permeability and gas exchange. 50 However, minute ventilation and oxygen consumption are increased. Despite systemic neutrophilia and activation of circulating monocytes, no change in cell number or phenotype was observed in the broncho-alveolar lavage fluid (BALF) after intravenous LPS, suggesting that the lung is a relatively insulated compartment. This compartmentalization was further demonstrated by the absence of change in cytokine mRNA expression in BALF despite high levels of circulating cytokines following endotoxin infusion. 50a While there was no basal increase in alveolar macrophage activation, they were primed for enhanced cytokine release upon subsequent stimulation. 51 
Neurological manifestations
Although a dose of endotoxin can induce systemic vasodilation in healthy subjects, it neither influences cerebral blood flow nor the cerebral metabolic rate for oxygen; 52 however, LPS can affect the central nervous system. Interestingly, Pollmacher et al. 53 examined whether there was any diurnal variation in the host response to endotoxin. When LPS was given at either 0900 h or 1900 h, increases in plasma IL-6 and TNF-α levels showed no variation, whereas the temperature, ACTH and cortisol responses were greater when LPS was given at 1900 h than at 0900 h. The authors concluded that it is not the endotoxin-induced release of cytokines that varies during the day, but rather the sensitivity of the targets of these cytokines. In another study to answer whether small increases in circulating cytokine levels directly affect neuropsychological function, Krabbe et al. 54 found that, at very low doses of endotoxin administration which did not affect fever or the hypothalamo-pituitary-adrenal axis, there was an increase in circulating IL-6 levels and impaired memory. Induction of pro-inflammatory cytokines by endotoxin had negative effects on emotional and memory functions. 55 Endotoxin increased α-MSH release in human and animals with high fever, suggesting that the neuropeptide is an endogenous modulator of host responses. 56 
Gastrointestinal and renal effects
Some early studies documented an increase in intestinal permeability following endotoxin infusion (see Lowry 3 ) More recent studies of endotoxin infusion to healthy volunteers show that colorectal permeability, luminal lactate concentrations, mucosal infiltration of inflammatory cells, epithelial apoptotic ratio and expression of iNOS were unaffected by endotoxin. This suggests that the gut is relatively resistant to the systemic inflammation induced by the infusion of 2 ng/kg body weight endotoxin. 57 The results of these studies of endotoxemia in healthy volunteers contrasts with recent findings in patients with inflammatory bowel disease and in infants with necrotizing enterocolitis in whom increased serum levels of endotoxin, LBP, soluble CD14 and pro-inflammatory cytokines correlated with disease activity. 58, 59 These differences emphasize that endotoxemia in healthy volunteers might not fully mimic the effects of endotoxemia during disease states. Healthy volunteers had a higher excretion of nitric oxide (NO) metabolites compared with control subjects and this was correlated with proximal tubule injury (based on urinary cytosolic glutathione-S-transferase-A1). Since this injury was reduced by an inhibitor of inducible NO synthase (aminoguanidine), they concluded that up-regulation of iNOS and subsequent NO production may be responsible for the LPS-induced renal proximal tubule damage. 60
Metabolic response to endotoxin infusion (Table 2)
Since one of the early responses to LPS is the activation of the pituitary-adrenal axis with a LPS dose-dependent increase in levels of plasma cortisol and growth hormone, its administration has been used as a diagnostic test for the evaluation of pituitary-adrenal function. 2 Several recent studies examined the metabolic response to endotoxin administration. The plasma levels of glucocorticoids and the adrenal androgens, dehydroepiandrosterone (DHEA) and DHEA-sulfate, increase early during sepsis, indicating that steroids can have an important role in host response to infection. 61 The increase in circulating cortisol during endotoxemia may alter host immune responses. 62 Indeed, there is a complex relationship between circulating stress hormones, such as cortisol and epinephrine, and the host immune response. Continuous infusion of epinephrine to subjects who subsequently were administered endotoxin resulted in a diminished TNF production, 63 while infusion of hydrocortisone increased IL-10 levels. 63, 64 In each study, the duration of stress hormone administration prior to endotoxin administration affected either the magnitude or pattern of cytokine response. In each study, however, there was a net anti-inflammatory effect. In an attempt to understand why the administration of high doses of steroids do not improve outcome from sepsis, while low doses may do so, de Kruif and colleagues 65 examined effects of increasing doses of prednisolone when given 2 h before intravenous endotoxin infusion. They found that prednisolone dose-dependently inhibited the LPSinduced release of pro-inflammatory cytokines and chemokines while it also enhanced the release of IL-10. This hormone had no effect on coagulation activation, however. 65 The induction of endogenous IL-1 during endotoxemia did not affect plasma thyroid hormone and TSH concentrations. 66 Sepsis is associated with a generalized catabolic response, with an induction of hyperglycemia, hypoaminoacidemia and an increase in circulating free fatty acids, as well as an increased in the uptake of glucose in peripheral tissues. 67 There was little to no detectable increase in circulating glucagons, insulin, epinephrine or cortisol, however. While LPS administration results initially in increased glucose utilization, this is followed by insulin resistance. 68 Acute endotoxemia did not increase levels of circulating leptin, an adipose tissue-derived weight-reducing hormone, which is increased in acute inflammation and may be involved in the anorexia and wasting syndrome associated with infection. 69 LPS does cause an increase in circulating levels of another adipose tissue-derived cytokine, adiponectin, which regulates the sensitivity of cells to insulin and prevents type II diabetes mellitus. 70 Endotoxin administration has a marked effect not only on amino acid but also trace metal metabolism. After infusion of LPS to healthy volunteers, there was a decrease in plasma concentration of total amino acids and of glutamine within 3 h of infusion. Similarly, muscle amino acid concentrations also decreased, perhaps due to the increased efflux of amino acids from skeletal muscle. 71 With inflammation there is a decrease in both serum iron and zinc levels. Kemna and colleagues 72 found that LPS-induced IL-6 rapidly induces hepcidin, a hepatic peptide hormone that regulates iron metabolism, and which is associated with hypoferremia. Zinc is a trace element that is required for protein synthesis, gene expression and immune function. Like iron, the levels of zinc decrease after trauma and stress. Transient hypozincemia following LPS infusion is the result of cytokinedirected internal redistribution of zinc. 73
Cytokine response to endotoxin (Table 3)
Following the initial descriptions of cytokines as immune modulators in the 1970s and 1980s, studies in various animal species examined both the cytokines induced and their temporal patterns following endotoxin infusion. 74, 75 Studies of endotoxin infusion in human subjects largely confirmed that humans, too, generate circulating cytokines following endotoxin infusion, but the absence in humans of some plasma cytokines found in animal studies (see below) may reflect the lower dose of endotoxin that must be given to human subjects. 2, 21, 76 TNF-α (formerly cachectin), IL-6 and GCSF have been best studied in humans. Robust levels of TNF-α appeared in the circulation of human subjects within 1-2 h of LPS infusion and returned to baseline by 3-5 h. 21, 67, 76 The splanchnic organs were a major site of production of TNF-α, and this was later confirmed in anhepatic baboons. 77 There is an initial rapid disappearance of 90 
Subjects
Two groups of 8 M Cytokines measured GCSF pre-treatment 2 h (group 1) versus 24 h (group 2) or placebo Objective
To assess the effects of GCSF on cytokine and neutrophil function
Results
Pretreatments with GCSF at 2 h and 24 h result in differential effects on LPS-induced cytokine release, but similar effects on LPS-induced PMN activation and expression of cell surface molecules. Finally, when given either 2 h or 24 h earlier, GCSF blocks LPS-induced pulmonary PMN accumulation To assess plasma concentrations of IL-1 and IL-1ra during endotoxemia
The predominant response to endotoxin in man is the production of antagonist rather than agonist To assess effects of endotoxemia on CCR2
Human endotoxemia induces down-regulation of CCR2 the cytokine followed by a slower terminal elimination. 78 The appearance of TNF-α was followed by down-modulation of monocyte and PMN TNF surface receptors 79 and an increase in soluble TNF receptors in the circulation. 80 TNF-α mediates many of the effects of endotoxin, including IL-1 receptor antagonist (IL-1ra) release, 81 and the systemic elaboration of prostacyclin; 82 however, TNF-α does not affect the release of secretory phospholipase A 2 , LPS binding protein or BPI, a cationic granular protein in neutrophils that neutralizes the biological activity of LPS, during sepsis or endotoxemia. 83, 84 Endotoxin also released IL-6, an endogenous mediator that participates in the metabolic and immune responses of the infected host, at 2-3 h and by 6 h returns to normal. 85 Increases in circulating IL-6 levels have been proposed as a measure of sepsis. [86] [87] [88] While LPS enhanced IL-6 release 300-fold after LPS infusion, there was no change in IL-6 mRNA expression, but there was an increased synthesis of the signaling receptor (gp130). 89 There have been studies on the induction of GCSF by LPS, as well as an examination of the modulatory effect of rGCSF on endotoxin-induced immune responses. GCSF changes the expression of cell surface molecules in neutrophils and blocks LPS-induced granulocyte accumulation in the lungs. 90 Following LPS infusion, while circulating GCSF levels peaked 4 h after LPS, there was a transient decrease in neutrophil (nadir at 2-4 h), but not monocyte, GCSF receptor expression. 91 GCSF has differential effects on LPS-induced cytokine release, but similar effects on LPS-induced activation and changes in neutrophils. 90 Finally, regardless of the effects of GCSF on LPS-induced cytokine release, the IL-6 G(-174)C promoter polymorphism did not significantly influence basal concentrations of IL-6 or peak IL-6 in human endotoxemia. 92 Recent studies examining the impact of polymorphisms in the fibrinogen and TNF-α genes on LPS-induced TNF-α have shown an effect for the former but not the latter. 93, 94 In contrast to the detection of circulating TNF-α, IL-6 and IL-8 after endotoxin infusion, IFN-γ, IL-1β and IL-2 have not been consistently detected in the circulation after LPS infusion to human subjects. 21, 67, 74, 76 In response to LPS, IL-1ra increases 100-fold greater than IL-1β so, for this cytokine, the production of an antagonist, not an agonist, is the natural response to endotoxin. 95 Despite its lack of detection in the circulation, there is indirect evidence of IFN-γ expression after LPS infusion. Ex vivo examination of whole blood from subjects administered LPS showed a reduced capacity to release IFN-γ after restimulation with LPS or for rIFN-γ to prime for LPSinduced TNF-α expression or up-regulate MHC class II expression. 96 The failure to detect some cytokines in the circulation after LPS infusion emphasizes the point that cytokines might be generated locally in specific tissues, and that circulating cytokines might not reflect the full spectrum of cytokines induced after systemic LPS ('tip of iceberg'). 97 One recent study compared protein and gene expression profiles in serum and circulating mononuclear cells after infusion of endotoxin. 98 While cytokine expression correlated well with gene expression, there were discrepancies noted over time which were attributed to tissue sources of cytokine other than from circulating mononuclear cells. Of interest, but not unexpectedly, the frequency, levels and duration of circulating cytokines in patients with sepsis, often failed to mirror what was observed following endotoxin infusion in man. 97, 99 This observation emphasizes the fact that the endotoxin infusion in humans is a useful model, but does have limitations in the types of information it can generate. As further evidence, Sprong et al. 100 reported that macrophage migration inhibitory factor (MIF), a mediator of innate immunity, was elevated in 20 patients with meningococcal infection and highest when shock was present; however, it was not detectable following the infusion of 2 ng/ml endotoxin to 8 healthy subjects.
Since IL-10 is considered to be an anti-inflammatory cytokine, it has been studied for its ability to reduce the responses to endotoxin. Pretreatment of subjects with rhIL-10 promoted anti-inflammatory effects, including the generation of less fever, cytokine responses and granulocyte accumulation in lungs during endotoxemia. The latter effect could be due to the ability of rIL-10 to inhibit the release of CC chemokines. 101 However, when given post-endotoxin infusion, rIL-10 had little antiinflammatory effect. 102 Indeed, one study showed that high-dose IL-10 treatment can induce undesired proinflammatory effects. 103 Chemokines, including IP-10, MCP-1, MIP1α and MIP1β, are produced after TNF-α, during clinical infection and endotoxin infusion. A portion of chemokines is produced locally. 104 After endotoxin infusion, IL-8 appears in human plasma at approximately 90 min. 105 Administration of LPS induces a down-regulation of monocyte CC chemokine receptor 2, while the plasma concentrations of its ligand, monocyte chemotactic protein 1 (MCP-1) increased. 106 This observation emphasizes the point that the net result of LPS-induced increases in circulating immune modulators cannot be properly interpreted without a knowledge of the concomitant behavior of its cognate receptor.
Immune cellular responses to endotoxin infusion (Table 4)
The effect of endotoxin on leukocytes and endothelial cells has been studied extensively. Neutrophils and monocytes differentially express surface TLRs, and endotoxemia differentially regulates TLR expression. 107, 108 The advent of molecular genetics has created To determine the effects and time-course of acute LPS challenge on inflammatory and cell-adhesion molecule markers shedding in the plasma as potential surrogates Results LPS induces an up-regulation of inflammatory stimuli leading to a short-term hyperactivation of leukocytes and a more sustained activation of platelets and endothelium To determine the release of NO, MMP-2 and MMP-9 following infusion of LPS
Results
The release of MMP-9, but not MMP-2 or NO, is a sensitive index of endotoxemia in humans. MMP-9 release may contribute to the pathogenesis of sepsis via its pro-inflammatory effects on the vasculature With an appreciation that mutations in the human Tolllike receptor 4 (hTLR4), the major LPS receptor on cells, may be associated with hyporesponsiveness to LPS. Calvano et al. 108 administered LPS to 57 subjects, of whom 8 had hTLR4 mutations. These latter subjects had similar responses to LPS as subjects without such mutations. 108 The expression of additional surface receptors is altered during endotoxemia. Triggering receptor expressed in myeloid cells-1 (TREM-1) amplifies the inflammatory response. Infusion of LPS to healthy subjects down-regulated the elevated baseline TREM-1 expression in PMNs, with a concomitant increase in soluble TREM-1. In contrast, there was a gradual increase in TREM-1 expression in monocytes. 109 With endotoxin infusion, increases in expression of CD64, a high-affinity FcγR1 receptor expressed by activated neutrophils, correlated with peak pro-inflammatory cytokine levels. 110 Endotoxin also causes monocytes and granulocytes to down-regulate IL-6R. 111 BPI expression by PMNs increases during Gram-negative bacterial sepsis or endotoxemia, but it is inadequate to compete with the much more abundant LBP to bind to LPS. 112 Urokinase plasminogen activator (uPAR or CD87) is an adhesion receptor on neutrophils and monocytes that is important for their chemotaxis. It forms functional complexes on the cell surface with another cell surface receptor, CD11b/CD18. LPS infusion enhances the expression of uPAR on the monocyte surface, thereby influencing its function 113 and it is released systemically after both induced endotoxemia and pyelonephritis. 114, 115 uPAR activity may an important factor in eliminating infection and protecting renal function in urosepsis. Endothelial cells are an important target of LPS. LPSinduced TNF-α mediates endotoxin-induced leukopenia and endothelial cell activation. 84 The endothelial cell adhesion molecules (E-selectin, P-selectin, and vascular cell adhesion molecule-1) are rapidly (within 1 h) shed into the circulation upon activation of endothelial cells. 115 Plasma soluble P-selectin had a delayed, but progressive, increase up to 8 h, while soluble V-CAM-1 levels had a progressive increase for up to 24 h. 116 Following endotoxin infusion there is also a rise in soluble L-selectin within 1 h which declines to baseline levels by 3.5 h.
The systemic inflammation (represented by fever and vasodilatation) reproduced by endotoxin infusion also can be measured both by complement activation (soluble complement factor complex [sC5-9]) and by increased levels of endothelin-1-like immunoreactivity (ET-1-LI), a measure of vascular endothelial activation. 117 In an attempt to discern whether endotoxin infusion could mimic an increase in the endothelial microvascular permeability associated with sepsis, van Eijk et al. 118 observed no increase in microvascular permeability in healthy subjects receiving endotoxin when measured by three different techniques. They concluded that the human endotoxin infusion model is not suitable for the study of this aspect of sepsis. 118 However, plasma obtained from human experimental endotoxemia, when added in vitro, increased the permeability of human umbilical venular endothelial cells. 119 Endothelial progenitor cells may contribute to the repair of injured endothelium and new blood vessel formation. Infusion of endotoxin leads to a decrease in circulating endothelial progenitor cells. 120 There are a limited number of studies that investigate the impact of endotoxemia on lymphocyte function. Activated lymphocytes undergo apoptosis causing endotoxin-induced lymphopenia. 121 Granzyme release, a marker of cytotoxic T lymphocyte and NK cell activity, is increased after the administration of endotoxin 122 and with bacterial infection. 123, 124 In turn, granzyme release may modulate cytokine activity. 123, 124 In addition to its effect on expression of cell surface molecules and cytokines, endotoxemia can induce intracellular inflammatory cascades. For example, endotoxin initiates intracellular signaling pathways leading to the activation of mitogen-activated protein kinases (MAPK) and ultimately to the generation of inflammatory mediators, including the release matrix metalloproteinases (MMPs). 123 MMP-9 is a sensitive and early marker for cell activation, and can have pro-inflammatory effects on the vasculature during sepsis. 124 The appearance of circulating serum leukocyte protease inhibitor (SLPI) after endotoxemia has been correlated with PMN-mediated organ dysfunction. 125
Inflammatory response inhibition (Table 5)
The infusion of endotoxin to human subjects has found considerable use in the evaluation of potential therapies that may inhibit inflammatory responses or treat sepsis. Following the exposure of macrophages to LPS, the phosphorylation of MAPKs such as p38 MAPK, leads to the downstream expression of pro-inflammatory cytokines. Three studies suggest that inhibitors of p38 MAPK and p42/p44 MAPK may be useful for antiinflammatory therapy. [126] [127] [128] Inhibition of p38MAPK by RWJ-67657 may correct the inflammatory immune response in sepsis. 128 Metalloproteinase (MP) inhibitors can be useful in treatment of TNF-α-induced inflammation without having any pro-inflammatory effects (e.g. increases in membrane-bound TNF-α and TNF-α receptor number). 129 CD14 is an important component of the LPS signaling complex which transfers LPS monomers onto the TLR4/MD2 signaling complex. Anti-CD14 antibody may decrease the inflammatory response in Gram-negative To determine the role of circulating leukocytes in CD14-dependent gene expression
Results
Peripheral blood cells are of negligible importance in LPS-induced production of inflammatory mediators in vivo and that LPS may activate genes via a CD14-independent pathway that is slower and less efficient To assess the influence of adenosine infusion on inflammatory and hemostatic parameters
Adenosine inhibits leukocyte adhesion and extravasation, mildly attenuates platelet responsiveness and soluble P-selectin release To determine the effect of nicotinamide on endotoxin-induced inflammatory responses
There was no effect on the inflammatory parameters by oral nicotinamide To assess plasma levels of TNF-α, IL-1 and IL-6 after intravenous administration of LPS with or without ibuprofen pretreatment
The cyclooxygenase inhibitor ibuprofen blunts the clinical response to endotoxin but augments circulating cytokine levels and leukocyte degranulation To assess the ability of IL-1ra to block the effects of low-dose endotoxin Results
IL-1 appears to be an important mediator in endotoxemia because some of its hematological and immunomodulatory effects can be blocked by IL-1ra To determine the efficacy of the endotoxin antagonist, E5531, in blocking this LPS-induced syndrome Results E5531 blocks the symptoms and signs and cytokine, white blood cell count, C-reactive protein, and cardiovascular response seen in experimental endotoxemia bacterial sepsis since its administration decreased the circulating levels of pro-inflammatory cytokines and some chemokines after LPS infusion; however, pretreatment with this MAb modestly reduced and delayed mRNA production of cytokines in circulating leukocytes. 130 Importantly, these investigators also observed that gene expression profiles in blood cells were poorly correlated with changes in plasma cytokine levels. 131 This observation may suggest that the origin of the cytokines detected from the circulation is not the circulating leukocytes, as discussed earlier. 67 In addition to its ability to bind and neutralize endotoxin, recombinant HDL may induce an anti-inflammatory effect by reducing the expression of CD14 on monocytes. 132 Several anti-inflammatory agents have been evaluated for their ability to reduce endotoxin-induced responses. Statins, used to control plasma cholesterol, also possess anti-inflammatory properties; however, when given to subjects following LPS infusion, no alteration in either plasma cytokine levels or total leukocyte count was observed. 133 Similarly, the induction of an 8-fold increase in circulating triglyceride levels with the administration of Intralipid, a triglyceride-rich fat emulsion, did not alter the inflammatory responses to endotoxin. 134 Thus, there have been mixed results with attempts to modify cholesterol, triglycerides and HDL in the inhibition of LPS-induced inflammation. Adenosine is a potential anti-inflammatory drug which inhibits leukocytes, platelet responsiveness, and soluble Pselectin release after LPS infusion. 135 Many patients treated for sepsis require dobutamine, a synthetic catecholamine that improves myocardial function. When LPS was administered to volunteers receiving a constant infusion of dobutamine, no alterations of inflammatory or coagulant pathways were observed compared to subjects receiving normal saline. 136 Similarly, other therapies 268 Bahador, Cross To assess the ability of E5564 to block the toxic activity of LPS Results E5564 blocks the effects of LPS failed to modify the inflammatory effect of endotoxemia. Enalapril, an angiotensin-converting enzyme inhibitor which may affect endothelial cell activation and oral nicotinamide, has no anti-inflammatory effects in endotoxemia. 137, 138 While pretreatment of subjects with ibuprofen blunts the clinical responses to endotoxin, it increases the plasma levels of TNF-α and IL-6 and increases circulating elastase which suggests it promotes leukocyte degranulation. 139 Calcitonin precursor (CTpr) has been proposed as both a marker and mediator of inflammation. Since administration of anti-inflammatory agents may reduce the levels of CTpr, the plasma levels of this protein might not be a reliable measure of inflammation. 140 Although the infusion of endotoxin does not appear to induce circulating IL-1 levels in human subjects,21,67 the ability of IL-1 receptor antagonist (IL-1ra) to block LPS-induced responses, suggests that IL-1 mediates some of the hematological and immunological effects of endotoxin,141 but does not appear to play a significant role in many other responses.142 Furthermore, in addition to the IL-1ra produced in response to LPS, the body produces corticosteroids which may act synergistically with IL-1ra to reduce inflammation. 143 Given the important role of the LPS receptor complex in initiating the inflammatory response to endotoxin, there have been attempts to block this response with compounds, such as monophosphoryl lipid A, that may interfere with the interaction of endotoxin with this receptor.144 E5564 and E5531, LPS receptor complex antagonists developed by Eisai, are the only inhibitors shown to block all of the human responses to intravenously administered LPS, including the symptoms and signs of cytokine release, white blood cell count, C-reactive protein, and cardiovascular response. 145 These findings have been reproducibly confirmed in a number of published studies. [146] [147] [148] [149] These studies demonstrate that effective antagonism at the level of the receptor is sufficient to block host recognition of LPS. A phase III clinical trial of E5564 (Eritoran ® ) for the treatment of sepsis is currently on-going.
Hematological response (Table 6)
After the infusion of LPS there is a well-documented biphasic response marked by an initial decrease in total leukocyte count followed by a rebound increase. 2, 3 Since leukocytosis can occur at a subpyrogenic dose of endotoxin, it may be the most sensitive indicator of human responsiveness to endotoxin. 2 At the doses of LPS given to man, there is no change in the platelet count, however.
LPS activates both coagulation and inflammatory pathways. Activation of endothelial cells by endotoxin up-regulates the expression of tissue factor and promotes coagulation. 129 Enhanced tissue factor gene expression activates coagulation after LPS challenge. 150 The ability of endotoxin-induced inflammation to promote coagulation was demonstrated in subjects receiving parenteral nutrition. 151 Thus, infections complicating parenteral nutrition may facilitate venous thrombosis. The levels of fibrinolytic/coagulation factors increase during an inflammatory state, 152 but only modestly. 2 Further, during endotoxin infusion factor XI is activated independently of the contact system (factor XII). 153 Within 1 h of endotoxin infusion, there was activation of the fibrinolytic system with increases in tissue plasminogen activator (tPA) levels and activity, 154 α 2 -plasmin inhibitor-plasmin complexes and a slower increase in plasminogen-activator inhibitor-1 (PAI-1). tPA functional activity was undetectable at 3 h. Thus, endotoxin activates the fibrinolytic system, but PAI-1 later inhibits endotoxin-induced fibrinolysis. Inflammation induces systemic thrombin formation which downregulates the expression of protease-activated receptors (PARs) on platelets. Since thrombin signaling is mediated in part by PARs, this down-regulation leads to a decreased responsiveness of platelets to subsequent stimulation. 155 Coagulation inhibitor response (Table 7) Endothelial cells are a key nexus in the interaction between inflammation and coagulation. There is some evidence that inhibition of coagulation can reduce inflammation and vice versa. For example, sE-selectin and mature von Willebrand factor (vWF) are good surrogate markers of endothelial cell activation. 156 The extent of activation of the endothelium during endotoxemia can be measured by mature von Willebrand factor and its pro-peptide 12. 157 Acetaminophen inhibits early von Willebrand factor elevation during human endotoxemia. This drug is also superior to aspirin as an antipyretic drug and it ameliorates the subjective symptoms. 158 Heparin preparations inhibit thrombin generation in the initial phase of experimental LPS-induced coagulation. 159 Heparin also has modest effects on cytokine production and endothelial cell activation, but unfractionated heparin can reduce L-selectin down-regulation and lymphocytopenia. 160 TNF-α also rapidly counteracted the fibrinolytic response and the long-lasting activation of thrombin. 161 A pro-inflammatory cytokine response accompanies activation of coagulation in primates, and inhibition of coagulation with tissue factor pathway inhibitor (TFPI) protects against lethal Gram-negative bacterial sepsis and attenuates coagulation activation. 162 In contrast, even though TFPI completely abrogated LPS-induced coagulation, inflammatory pathway activation still occurred. 163 TFPI pretreatment did not alter leukocyte activation, chemokine release, endothelial cell activation or acute phase response. Since inhibition of LPSinduced plasmin activation did not inhibit the introduction of inflammatory mediators, plasmin generation is not likely to have a role in the activation of the inflammatory pathway. 164 Since endotoxin has prominent effects on the coagulation/fibrinolytic systems, the use of coagulation inhibitors as potential therapy for sepsis has been extensively studied. CD14 and activation of p38 MAPK are potential factors in the activation of coagulation, fibrinolysis, and endothelial cell response in endotoxemia. 165 Blockade of the CD14 component of the LPS receptor complex blocks LPS-induced inflammatory changes, but little is known of CD14 blockade on the procoagulant and fibrinolytic responses. Therefore, the effect of a recombinant chimeric mAb directed against CD14 on LPS induced responses was examined. Based on the activity of this mAb, some responses (generation of thrombin-antithrombin complexes and soluble fibrin, activation of fibrinolysis and later inhibition of fibrinolysis) were CD14-dependent, while others (coagulant activity, increased soluble thrombomodulin levels) proceed along CD14-independent pathways. 166 rHDL modifies the procoagulant state in endotoxemia, 167 and this may occur, in part, though its effect on CD14 expression. The continuous infusion of epinephrine results in antithrombotic effects during a subsequent endotoxemia through the concurrent inhibition of coagulation and the stimulation of fibrinolysis. 168 Thus, endogenous and administered epinephrine can limit disseminated intravascular coagulation (DIC) during systemic inflammatory response syndrome (SIRS). Other strategies to 270 Bahador, Cross The effects of systemic thrombin formation on the regulation of PAR1 and the associated responsiveness of human platelets to TRAP. Endotoxin (2 ng/kg) Results PAR1 expression is down-regulated on platelets during systemic thrombin formation induced by inflammation, this results in decreased responsiveness of platelets to subsequent stimulation of the PAR1 receptor To assess the relationship between cytokine release and hematological abnormalities
Results
These results show that endotoxin induces an early, rapidly counteracted fibrinolytic response, and a more long-lasting activation of thrombin by a mechanism other than contact system activation. In addition, endotoxin-induced leukopenia and endothelial cell activation are mediated by TNF To assess the effect of TFPI on LPS-induced inflammatory response
Complete prevention of coagulation activation by TFPI does not influence activation of inflammatory pathways during endotoxemia To determine the pharmacokinetics and pharmacodynamics of rNAPc2 and its effect on endotoxin-induced coagulation and inflammation Results rNAPc2, a potent inhibitor of TF/FVIIa, completely blocked endotoxin-induced thrombin generation without affecting the fibrinolytic response. In addition, rNAPc2 attenuated the endotoxin-induced rise in IL-10, without affecting the increase in other cytokines To determine the effects of IL-10 on LPS-induced activation of the hemostatic mechanisms Results
These results indicate that rhIL-10, besides its well-described inhibitory effects on cytokine release, potently modulates the fibrinolytic system and inhibits the coagulant responses during endotoxemia To assess the mechanism of TPO release
Endotoxemia enhances TPO plasma levels independently of the degree of coagulation induction, which eventually results in increased platelet numbers. Of potential clinical interest is the observation that the direct thrombin inhibitor lepirudin, in contrast to heparins, mitigated LPS-induced platelet activation limit the effect of LPS on the coagulation system have been examined. rBPI 23 reduces both fibrinolytic and coagulation systems. 169 rNAPc2 blocks thrombin generation and IL-10 production. 170 rhIL-10 inhibits coagulant responses by modulating the fibrinolytic system. 171 Increased thrombopoietin (TPO) during endotoxemia increases platelet numbers, so lepirudin can mitigate LPS-induced platelet activation and serve as a potential therapeutic agent. 172 Additionally, platelet aggregation is mediated, in part, by glycoprotein (GP) IIb/IIIa integrin receptors on their surface. Consequently, reagents that block there receptors are used widely in the management of coronary disease patients, such as those receiving coronary stents or angioplasty. The GP IIb/IIIa inhibitors, eptifibatide or tirofiban, had no effect on coagulation activation during LPS infusion, however. 173 The protein C pathway has anti-inflammatory and anti-coagulant properties. Since activated protein C levels decrease during sepsis, the administration of a recombinant human activated protein C (rhAPC) might be expected to provide anti-inflammatory and anti-coagulant effects. Mean arterial pressure improved with the infusion of drotrecogin alfa (activated), a rhAPC, before endotoxin infusion. 174 rhAPC decreased coagulation but, unlike many anti-coagulants, did not inhibit tissue factor-mediated coagulation. 175 This protein has since been approved for treatment of septic shock under the trade name, Xigris ® .
CONCLUDING REMARKS
For well over a century, endotoxin has been intentionally administered to humans for therapeutic purposes, for the evaluation of anti-inflammatory reagents as well as to address basic scientific questions of endotoxin biology. Much has been learned from the use of this model, and it has proved to be remarkably safe. Well over 1000 subjects have been studied, yet we were able to find documentation of only five serious adverse events, 38, 39 and these were in subjects who were later shown to have vagal hypersensitivity. As appropriately observed by Lowry and Munford, when used as a paradigm for human sepsis, several caveats for the human endotoxin infusion studies must be kept in mind. 3, 176 Such studies are usually done in healthy subjects that lack the co-morbidities which complicate patients with sepsis. Further, stress hormones markedly reprogram the response to To determine whether rhAPC acts as an anticoagulant or anti-inflammatory drug
Results
Even low-grade endotoxemia induces significant protein C activation. Infusion of rhAPC decreases 'spontaneous' activation of coagulation but does not blunt LPS-induced, TF-mediated coagulation in healthy volunteers LPS (see above). During sepsis, exposure to endotoxin probably occurs in low doses intermittently over extended periods of time from a tissue site of uncontrolled infection, and not as a single bolus into the systemic compartment, as in the human infusion model. Thus, the kinetics and mechanisms of endotoxin inactivation may differ dramatically in the two situations. In a prospective study with serial endotoxin determinations of 110 patients admitted to a medical intensive care unit with shock, 43 of 100 patients with septic shock had detectable endotoxin compared to one in ten patients with shock due to non-septic causes. 177 Thus endotoxemia in humans is intermittent and low grade. Further, in the human endotoxin infusion model, therapeutic agents are typically given before the endotoxin, and not after the onset of sepsis as is usually done in clinical practice.
In the human infusion model, one is unable to measure tissue responses, and these responses may be the more relevant than responses in the circulation. Indeed, studies have shown a discrepancy between cytokine responses measured in the plasma and what is expressed in the circulating cells. 97 This emphasizes that, with the possible expression of TNF-α, 67 relatively little is known about the cellular origin of the circulating cytokines in the endotoxin infusion model. Another issue raised by the endotoxin infusion model is the relative role of endotoxin, relative to other microbial components, in sepsis. While this subject is not the focus of this review, Senterfitt and Shands 178 demonstrated many years ago that mice moribund after Salmonella infection had ~10 9 CFU/g tissue. They calculated that the total amount of endotoxin at death was far below that required to kill mice if given as a pure reagent. The human endotoxin infusion model examines only one initiator of the septic response as opposed to the multiple TLR agonists that are presented to the immune system on intact bacteria. It is possible that multiple components of the bacteria that are TLR ligands (e.g. outer membrane proteins, nucleic acids) might synergize with the relatively low levels of endotoxin to induce the lethal inflammatory state. Finally, a number of therapeutic agents tested in the human endotoxin infusion model have progressed to clinical trials (e.g. rBPI, IL-1ra, anti-TNF mAbs, activated protein C). The lack of studies that carefully correlate the findings from previously conducted human infusion studies with an examination of similar parameters in the corresponding clinical studies constitutes a missed opportunity to assess the utility of the human endotoxin infusion studies as a guide to the planning and conduct of clinical studies for the treatment of sepsis and other inflammatory conditions. While it is unlikely that endotoxin will be administered to humans for therapeutic purposes, it will continue to be a useful model to further our understanding of the human response to inflammation, and as a first step in the evaluation of anti-inflammatory therapies. Future studies must be conducted with an appreciation of the limitations of this model.
